Drug Discovery World

MARCH 7, 2023

Indeed, QCRI is currently working with other organisations in Qatar including Qatar Biobank, to further research and develop data sets that contain whole genome sequences. “Current work at QCRI focuses on developing polygenic risk scores for complex diseases and traits using local Qatari data.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Drug Discovery World

OCTOBER 12, 2022

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Phil Jones, VP Discovery, RxBiologics, on: ‘Antibody discovery using the Galaxy library platform’.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

MARCH 16, 2022

The research scientist at the Max Planck Institute for Medical Research received the award in recognition of his ground-breaking work in establishing various approaches to protein labeling in living cells that have enabled far-reaching advances in chemical and cell biology. Protein labeling (e.g. Dr. Connor W. billion euros.

Protein 52

Protein Scientist Gene Development 52

XTalks

DECEMBER 13, 2023

In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. For the three and six months ending June 30, 2023, R&D expenses reached $19.2

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

SEPTEMBER 29, 2021

These data reinforce the importance of early comprehensive genomic testing to uncover actionable oncogenic drivers, including NTRK gene fusions, to assist identify patients who are presumably to profit from a targeted treatment approach.”. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros.

Gene 52

Gene Protein Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Delveinsight

DECEMBER 7, 2020

Unlike most other industries, in MedTech, AI is not confined to sales and operations ends of the value chain. The test identifies Ubiquitin and Glial Fibrillary Acidic Protein (GFAP)- 2 brain-specific protein biomarkers- that appear rapidly in the blood of a patient after a brain injury.

Protein 56

Protein Insulin Hormones FDA Approval 56

XTalks

DECEMBER 4, 2023

CAR T-cell therapies, which have been transformative in several blood cancers, involve extracting a patient’s own T cells, genetically modifying them with a chimeric antigen receptor (CAR) targeting specific proteins on cancer cells and then reinfusing them into the body. billion in sales in the first three quarters of 2023.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

pharmaphorum

APRIL 14, 2021

The drug has gone on to become a huge success, generating sales of nearly $1.8 These cancer cells have switched to this backup system to repair DNA damage and by turning it off, PARP inhibitors cause them to die from a process known as “synthetic lethality” as mutations in their genome run out of control.

Drugs 57

Drugs DNA Genome Genomics 57

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca also wanted to endure shareholder value through global power and reach in sales and marketing, greater financial strategic flexibility and the creation of a stronger R&D platform for innovation-led growth. The merger of Astra and Zeneca aimed to improve the combined companies’ ability to deliver long term growth.

Pharma Companies 113

Pharma Companies Sales Vaccination Vaccine 113

The Pharma Data

MAY 4, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

HR 52

HR Protein In-Vitro Medicine 52

Delveinsight

DECEMBER 13, 2020

The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

DECEMBER 28, 2020

Cyclophilins, of which there are 17 known isoforms in humans, play a central role in protein folding and contribute to numerous biological effects including inflammation and fibrosis, to name a few. Hepion’s lead novel drug candidate, CRV431, is a pan-cyclophilin inhibitor that inhibits multiple forms of cyclophilins.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Development 40

The Pharma Data

SEPTEMBER 16, 2020

Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from Blood First Assay Screening Trial (BFAST) and comparison with real-world data (RWD). Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH). Lung cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

JULY 23, 2021

In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. In 2020, Roche invested CHF 12.2

Antibody 52

Antibody Medicine Production In-Vitro 52